- All News
- In the News
- Press Releases
Immunexpress Continues Executive Team Expansion with Addition of Fayyaz Memon as VP of Regulatory Affairs & Quality
SEATTLE, July 10, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced that Fayyaz Memon, MBA, MS, has joined the company's Executive Team as Vice President of Regulatory Affairs and Quality. "Mr. Memon arrives at a key time for the Company as we continue to fortify our leadership team with accomplished individuals well-versed in the life sciences...
People in the News: Rolland Carlson, Tanja Dowe, Katleen Verleysen
Accomplished industry leaders join recently appointed CEO, Dr. Rolland Carlson, to expand on the comprehensive experience of the Board.
Appointments and advancements – Rolland Carlson, Tanja Dowe, Katleen Verleysen
Immunexpress strengthens Board of Directors with key appointments.
Immunexpress Strengthens Board of Directors with Key Appointments
Accomplished Industry Leaders Join Recently Appointed CEO, Dr. Rolland Carlson, to Expand on the Comprehensive Experience of the Board SEATTLE, May 15, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced the appointment of three new members to its Board of Directors. Rolland Carlson, PhD, Tanja Dowe and Katleen Verleysen, PhD, have joined the company's board, while Bea Arnold, PhD, has stepped...
Molecular Laboratory Test Can Discriminate Sepsis From Noninfectious SIRS
Design and results of clinical trials that led to FDA clearance of SeptiCyte™ LAB published in the American Journal of Respiratory and Clinical Care Medicine.
Product Briefs – SeptiCyte LAB
Immunexpress, Inc. published in the American Journal of Respiratory and Clinical Care Medicine the design and results of clinical trials validating SeptiCyte™ LAB in the discrimination of sepsis from non-infectious systemic inflammatory response syndrome (SIRS) in the Intensive Care Unit (ICU) of hospitals.
SeptiCyte™ LAB Differentiates Sepsis from SIRS in the ICU
Design and results of clinical trials that led to FDA clearance of SeptiCyte™ LAB published in the American Journal of Respiratory and Clinical Care Medicine SEATTLE, May 9, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced the publication in the American Journal of Respiratory and Clinical Care Medicine of the design and results of clinical trials...
Immunexpress Appoints Rolland Carlson, Ph.D., as Chief Executive Officer
Industry veteran brings a successful track record fundraising and launching commercial products Appointment strengthens the leadership team and positions the company for its targeted commercial launch SEATTLE, April 10, 2018 – Immunexpress, Inc. today announced the appointment of Rolland D. Carlson, Ph.D., as chief executive officer, effective April 9,...
Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU
Miller et al., American Journal of Respiratory and Critical Care Medicine | SeptiCyte LAB appears to be a promising diagnostic tool to complement physician assessment of infection likelihood in critically ill adult patients with systemic inflammation.
Biocartis Partnership May Enable Immunexpress to Move Sepsis Test to Point of Care
Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company and Immunexpress have entered into a partnership agreement aimed at the development and commercialization of Immunexpress’ SeptiCypte™ test for use on Biocartis’ sample-to-result Idylla™ platform.
Brief-Biocartis & Immunexpress Partnership For A Sepsis Host Immune Response Test
Immunexpress and Biocartis enter an agreement to develop and commercialize SeptiCyte™ technology for use on sample-to-result Idylla™ platform.